Immunome is a clinical-stage targeted oncology company focused on developing targeted therapies to improve outcomes for cancer patients. The company has an innovative portfolio of therapeutics, including antibody-drug conjugates and treatments for desmoid tumors.

Immunome

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.

Jaume Pons

ALX Oncology Holdings Inc.

Asher Bio is a company focused on developing cis-targeted immunotherapies that engage two receptors on the same immune cell to provide a new level of selectivity in immune cell activation.

Asher Bio

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.

Friedrich Bayer

Johann Friedrich Weskott

Bayer Aktiengesellschaft

Immunome, Inc. | 6,762 followers on LinkedIn. Developing antibody-based therapeutics by unlocking the human memory B cell response. | Immunome is a biotechnology company with a growing pipeline of cancer immunotherapies fueled by the human immune system. Our unique and powerful immunotherapy discovery engine leverages “most highly educated” immune systems from patients who have already learned how to fight off their disease. This proprietary technology platform enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens.

Metric
Company Name	Immunome	ALX Oncology Holdings Inc.	Asher Bio	Bayer Aktiengesellschaft
Symbol		ALXO		BAYN
MSH ID	COM:IMMUNOME	COM:ALXONCOLOGY	COM:ASHERBIO	COM:BAYER
Market	PRIVATE	STOCKS	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare	Healthcare & Health Services	Healthcare
Industry	Pharmaceuticals	Biotechnology	Biotechnology	Drug Manufacturers - General
Country	US	US	US	DE
Stage
Employee Count		74	36	98.19K
Website	immunome.com	alxoncology.com	asherbio.com	bayer.com
LinkedIn	immunome-inc-		asher-biotherapeutics	bayer
Founders

Metric
Market Cap	352.20M		27.44B
Enterprise Value
Monthly Web Traffic		2.08K
Web Traffic Growth		-0.18
Valuation
Raised Capital

Metric
Revenue				50.32B
Revenue (LTM)
Revenue (NTM)
Gross Profit				29.46B
EBITDA				13.04B
Operating Income				8.88B
Net Income				-3.11B
EPS				-3.16
Diluted EPS				-3.16
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin				0.59
Operating Profit Margin				0.08
EBITDA Margin				0.26
Net Profit Margin				-0.03
Return on Equity				-0.04
Return on Assets				-0.01
Return on Capital Employed				0.04

COM:IMMUNOME

Immunome

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio				-7.66
P/B Ratio				0.84
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio				0.63
EV Multiple				-0.89

Metric
Days Sales Outstanding
Days Payables Outstanding				118.44
Days Inventory Outstanding				257.77
Operating Cycle				389.93
Cash Conversion Cycle				270.05
Asset Turnover				0.39

Metric
Operating Cash Flow				4.29B
Free Cash Flow				1.38B
Cash Flow to Debt				0.16
Operating Cash Flow/Sales				0.16
Free Cash Flow Yield				-0.02

Metric
Cash & Equivalents				6.24B
Accounts Receivable				727.74M
Inventory				14.73B
Goodwill				34.12B
Debt to Capitalization				0.57
Debt to Assets				0.41
Current Ratio				1.13
Quick Ratio				0.87

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue				0.12
SG&A to Revenue				0.05